hope rugo, md, considers chemotherapy recommendations based on findings from keynote-355
Published 3 years ago • 107 plays • Length 1:26
Download video MP4
Download video MP3
Similar videos
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
1:42
hope rugo, md, offers key takeaways for physicians regarding keynote-355
-
2:02
hope rugo, md, considers the incidence of tnbc and what makes this disease so difficult to treat
-
1:03
debra patt, md, phd, mba, comments on findings from the keynote-355 trial
-
3:31
hope rugo, md, examines data from the destiny-breast01 clinical study presented at sabcs 2020
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
10:31
life on standby | ep3 : living with triple negative breast cancer
-
3:24
new hope in pancreatic cancer at johns hopkins
-
13:44
first chemo treatment for tnbc. keynote 522
-
3:23
ucsf at #aacr24: hope rugo, md | clinical trials discussant on "advanced in targeted therapy"
-
4:50
hope rugo, md, provides perspective on the clinical progress of cdk 4/6 inhibitors in breast cancer
-
2:21
fda approves pembrolizumab in combination with chemotherapy
-
4:01
keynote-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated aes
-
4:42
elizabeth mittendorf, md, phd, considers key takeaways from the impassion-131 presented at esmo 2020
-
1:33
dr. hope rugo on the first-line superiority of paclitaxel for advanced breast cancer
-
4:15
hope rugo, md, fasco at #asco23
-
1:00:31
inspired | beyond the white coat with dr. hope rugo
-
5:40
hope rugo, oncologist shelley hwang, surgeon (v2)
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
3:23
should chemotherapy be used in post-menopausal patients with low genomic risk hr breast cancer?
-
2:10
message from dr hope rugo on covid 19 and cancer patients
Clip.africa.com - Privacy-policy